Highlights

Public-Private Partnership Between NIAID and Sequella Yields New TB Drug for Clinical Testing Statement from the NIH
Read More

Highlights

Woman CEO's Proving Glass Ceiling Can be Broker
Read More

Welcome to Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats.

Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

© 2009 Sequella, Inc.